Skip to main content
NCBI home page
Heart logoLink to Heart
. 1996 Aug;76(2):109–116. doi: 10.1136/hrt.76.2.109

K+ channel opening: a new drug principle in cardiovascular medicine.

J E Nielsen-Kudsk 1, S Boesgaard 1, J Aldershvile 1
PMCID: PMC484456  PMID: 8795471

Full text

PDF
109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auchampach J. A., Maruyama M., Cavero I., Gross G. J. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation. 1992 Jul;86(1):311–319. doi: 10.1161/01.cir.86.1.311. [DOI] [PubMed] [Google Scholar]
  2. Auchampach J. A., Maruyama M., Cavero I., Gross G. J. The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther. 1991 Dec;259(3):961–967. [PubMed] [Google Scholar]
  3. Aversano T., Ouyang P., Silverman H. Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation. Circ Res. 1991 Sep;69(3):618–622. doi: 10.1161/01.res.69.3.618. [DOI] [PubMed] [Google Scholar]
  4. Barnes P. J., Liu S. F. Regulation of pulmonary vascular tone. Pharmacol Rev. 1995 Mar;47(1):87–131. [PubMed] [Google Scholar]
  5. Black S. C., Lucchesi B. R. Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res. 1994 Jun;28(6):923–929. doi: 10.1093/cvr/28.6.923. [DOI] [PubMed] [Google Scholar]
  6. Bolotina V. M., Najibi S., Palacino J. J., Pagano P. J., Cohen R. A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994 Apr 28;368(6474):850–853. doi: 10.1038/368850a0. [DOI] [PubMed] [Google Scholar]
  7. Cavero I., Djellas Y., Guillon J. M. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther. 1995 Mar;9 (Suppl 2):245–255. doi: 10.1007/BF00878472. [DOI] [PubMed] [Google Scholar]
  8. Coetzee W. A. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc Drugs Ther. 1992 Jun;6(3):201–208. doi: 10.1007/BF00051140. [DOI] [PubMed] [Google Scholar]
  9. Cook N. S., Chapman I. D. Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma. Cardiovasc Drugs Ther. 1993 Aug;7 (Suppl 3):555–563. doi: 10.1007/BF00877621. [DOI] [PubMed] [Google Scholar]
  10. D'Alonzo A. J., Grover G. J. Potassium channel openers are unlikely to be proarrhythmic in the diseased human heart. Cardiovasc Res. 1994 Jun;28(6):924–929. doi: 10.1093/cvr/28.6.924. [DOI] [PubMed] [Google Scholar]
  11. Daut J., Maier-Rudolph W., von Beckerath N., Mehrke G., Günther K., Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science. 1990 Mar 16;247(4948):1341–1344. doi: 10.1126/science.2107575. [DOI] [PubMed] [Google Scholar]
  12. Edwards G., Weston A. H. Pharmacology of the potassium channel openers. Cardiovasc Drugs Ther. 1995 Mar;9 (Suppl 2):185–193. doi: 10.1007/BF00878465. [DOI] [PubMed] [Google Scholar]
  13. Escande D., Cavero I. K+ channel openers and 'natural' cardioprotection. Trends Pharmacol Sci. 1992 Jul;13(7):269–272. doi: 10.1016/0165-6147(92)90083-i. [DOI] [PubMed] [Google Scholar]
  14. Frampton J., Buckley M. M., Fitton A. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 1992 Oct;44(4):625–655. doi: 10.2165/00003495-199244040-00008. [DOI] [PubMed] [Google Scholar]
  15. Friedel H. A., Brogden R. N. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs. 1990 Jun;39(6):929–967. doi: 10.2165/00003495-199039060-00008. [DOI] [PubMed] [Google Scholar]
  16. Furukawa K., Itoh T., Kajiwara M., Kitamura K., Suzuki H., Ito Y., Kuriyama H. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary arteries. J Pharmacol Exp Ther. 1981 Jul;218(1):248–259. [PubMed] [Google Scholar]
  17. Ghaleh B., Dubois-Randé J. L., Hittinger L., Giudicelli J. F., Berdeaux A. Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br J Pharmacol. 1995 Jan;114(2):496–502. doi: 10.1111/j.1476-5381.1995.tb13254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gross G. J. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol. 1995 Mar-Apr;90(2):85–88. doi: 10.1007/BF00789438. [DOI] [PubMed] [Google Scholar]
  19. Gross G. J., Auchampach J. A. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992 Feb;70(2):223–233. doi: 10.1161/01.res.70.2.223. [DOI] [PubMed] [Google Scholar]
  20. Grover G. J., D'Alonzo A. J., Parham C. S., Darbenzio R. B. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol. 1995 Jul;26(1):145–152. doi: 10.1097/00005344-199507000-00023. [DOI] [PubMed] [Google Scholar]
  21. Grover G. J., McCullough J. R., D'Alonzo A. J., Sargent C. A., Atwal K. S. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol. 1995 Jan;25(1):40–50. doi: 10.1097/00005344-199501000-00008. [DOI] [PubMed] [Google Scholar]
  22. Grover G. J. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol. 1994;24 (Suppl 4):S18–S27. [PubMed] [Google Scholar]
  23. Grover G. J., Sleph P. G., Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation. 1992 Oct;86(4):1310–1316. doi: 10.1161/01.cir.86.4.1310. [DOI] [PubMed] [Google Scholar]
  24. Imamura Y., Tomoike H., Narishige T., Takahashi T., Kasuya H., Takeshita A. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol. 1992 Aug;263(2 Pt 2):H399–H404. doi: 10.1152/ajpheart.1992.263.2.H399. [DOI] [PubMed] [Google Scholar]
  25. Katz A. M. Cardiac ion channels. N Engl J Med. 1993 Apr 29;328(17):1244–1251. doi: 10.1056/NEJM199304293281707. [DOI] [PubMed] [Google Scholar]
  26. Kirsch G. E., Codina J., Birnbaumer L., Brown A. M. Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol. 1990 Sep;259(3 Pt 2):H820–H826. doi: 10.1152/ajpheart.1990.259.3.H820. [DOI] [PubMed] [Google Scholar]
  27. Knight C., Purcell H., Fox K. Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther. 1995 Mar;9 (Suppl 2):229–236. doi: 10.1007/BF00878470. [DOI] [PubMed] [Google Scholar]
  28. Komaru T., Lamping K. G., Eastham C. L., Dellsperger K. C. Role of ATP-sensitive potassium channels in coronary microvascular autoregulatory responses. Circ Res. 1991 Oct;69(4):1146–1151. doi: 10.1161/01.res.69.4.1146. [DOI] [PubMed] [Google Scholar]
  29. Kukuljan M., Labarca P., Latorre R. Molecular determinants of ion conduction and inactivation in K+ channels. Am J Physiol. 1995 Mar;268(3 Pt 1):C535–C556. doi: 10.1152/ajpcell.1995.268.3.C535. [DOI] [PubMed] [Google Scholar]
  30. Mellemkjaer S., Nielsen-Kudsk J. E. Effects of levcromakalim and glibenclamide on paced guinea-pig atrial strips exposed to hypoxia. Eur J Pharmacol. 1995 Apr 13;277(1):51–56. doi: 10.1016/0014-2999(95)00061-o. [DOI] [PubMed] [Google Scholar]
  31. Mellemkjaer S., Nielsen-Kudsk J. E. Glibenclamide inhibits hypoxic relaxation of isolated porcine coronary arteries under conditions of impaired glycolysis. Eur J Pharmacol. 1994 Aug 3;270(4):307–312. doi: 10.1016/0926-6917(94)90006-x. [DOI] [PubMed] [Google Scholar]
  32. Merkel L. A., Lappe R. W., Rivera L. M., Cox B. F., Perrone M. H. Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels. J Pharmacol Exp Ther. 1992 Feb;260(2):437–443. [PubMed] [Google Scholar]
  33. Nelson M. T., Quayle J. M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995 Apr;268(4 Pt 1):C799–C822. doi: 10.1152/ajpcell.1995.268.4.C799. [DOI] [PubMed] [Google Scholar]
  34. Nielsen-Kudsk J. E., Bang L. Effects of pinacidil and other cyanoguanidine derivatives on guinea-pig isolated trachea, aorta and pulmonary artery. Eur J Pharmacol. 1991 Aug 16;201(1):97–102. doi: 10.1016/0014-2999(91)90328-n. [DOI] [PubMed] [Google Scholar]
  35. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983 Sep 8;305(5930):147–148. doi: 10.1038/305147a0. [DOI] [PubMed] [Google Scholar]
  36. Post J. M., Hume J. R., Archer S. L., Weir E. K. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol. 1992 Apr;262(4 Pt 1):C882–C890. doi: 10.1152/ajpcell.1992.262.4.C882. [DOI] [PubMed] [Google Scholar]
  37. Quast U., Guillon J. M., Cavero I. Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res. 1994 Jun;28(6):805–810. doi: 10.1093/cvr/28.6.805. [DOI] [PubMed] [Google Scholar]
  38. Quast U. Potassium channel openers: pharmacological and clinical aspects. Fundam Clin Pharmacol. 1992;6(7):279–293. doi: 10.1111/j.1472-8206.1992.tb00122.x. [DOI] [PubMed] [Google Scholar]
  39. Quayle J. M., Standen N. B. KATP channels in vascular smooth muscle. Cardiovasc Res. 1994 Jun;28(6):797–804. doi: 10.1093/cvr/28.6.797. [DOI] [PubMed] [Google Scholar]
  40. Schmid-Antomarchi H., De Weille J., Fosset M., Lazdunski M. The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. J Biol Chem. 1987 Nov 25;262(33):15840–15844. [PubMed] [Google Scholar]
  41. Smits P., Thien T. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM? Diabetologia. 1995 Jan;38(1):116–121. doi: 10.1007/BF02369361. [DOI] [PubMed] [Google Scholar]
  42. Thomas P., Dixon M. S., Winterton S. J., Sheridan D. J. Acute haemodynamic effects of cromakalim in patients with angina pectoris. Br J Clin Pharmacol. 1990 Mar;29(3):325–331. doi: 10.1111/j.1365-2125.1990.tb03643.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tomai F., Crea F., Gaspardone A., Versaci F., De Paulis R., Penta de Peppo A., Chiariello L., Gioffrè P. A. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994 Aug;90(2):700–705. doi: 10.1161/01.cir.90.2.700. [DOI] [PubMed] [Google Scholar]
  44. Wilde A. A., Janse M. J. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res. 1994 Jan;28(1):16–24. doi: 10.1093/cvr/28.1.16. [DOI] [PubMed] [Google Scholar]
  45. Yao Z., Gross G. J. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation. 1994 Apr;89(4):1769–1775. doi: 10.1161/01.cir.89.4.1769. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES